Literature DB >> 19681790

Management of congenital nasolacrimal duct obstruction.

Yasuhiro Takahashi1, Hirohiko Kakizaki, Weng O Chan, Dinesh Selva.   

Abstract

Our review aims to provide an update of management protocols for congenital nasolacrimal duct obstruction (CNDO). Although early probing performed before the age of 1 year was traditionally recommended, many reports have since confirmed high frequencies of spontaneous resolution during the first year of life. Accordingly, a 'wait-and-see' approach, combined with conservative therapies, is judged to be the best option in infants aged<1 year. By contrast, persistent obstruction beyond 1 year of age warrants probing as a first-line interventional therapy. However, the optimal timing for probing remains controversial. Although there remains a high possibility of spontaneous resolution after the first year of age, this must be balanced against the decrease in success rates for probing that accompanies advancing age. If conservative management fails, persistent CNDO beyond 1 year of age should be managed either by further observation or by primary probing according to the severity of symptoms. In patients in whom probing fails, advanced treatment such as balloon catheter dilation, silicone tube intubation or dacryocystorhinostomy may be considered.

Entities:  

Mesh:

Year:  2009        PMID: 19681790     DOI: 10.1111/j.1755-3768.2009.01592.x

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  18 in total

1.  [Treatment of congenital lacrimal duct obstruction: A prospective clinical cohort study].

Authors:  J Heichel; F Bachner; A Schmidt-Pokrzywniak; H-G Struck; U Stuhlträger; T Bredehorn-Mayr
Journal:  Ophthalmologe       Date:  2015-10       Impact factor: 1.059

2.  A comparison between monocanalicular and pushed monocanalicular silicone intubation in the treatment of congenital nasolacrimal duct obstruction.

Authors:  Dima Andalib; Hossein Mansoori
Journal:  Int J Ophthalmol       Date:  2014-12-18       Impact factor: 1.779

Review 3.  [Congenital nasolacrimal duct obstruction from an ophthalmologist's point of view : Causes, diagnosis and staged therapeutic concept].

Authors:  J Heichel; T Bredehorn-Mayr; H-G Struck
Journal:  HNO       Date:  2016-06       Impact factor: 1.284

4.  Effects of medication methods after simple and effective probing of lacrimal passage.

Authors:  Bin Lu; Hua-Ying Xie; Cai-Ping Shi; Chun-Si Xu; Mei-Hong Gu
Journal:  Int J Ophthalmol       Date:  2014-10-18       Impact factor: 1.779

5.  Probing for congenital nasolacrimal duct obstruction in older children.

Authors:  Bahram Eshragi; Masoud Aghsaei Fard; Babak Masomian; Mohammadreza Akbari
Journal:  Middle East Afr J Ophthalmol       Date:  2013 Oct-Dec

6.  Incidence and clinical characteristics of congenital nasolacrimal duct obstruction.

Authors:  Saraniya Sathiamoorthi; Ryan D Frank; Brian G Mohney
Journal:  Br J Ophthalmol       Date:  2018-06-06       Impact factor: 4.638

Review 7.  [Minimally invasive diagnostics and therapy of congenital nasolacrimal duct obstruction].

Authors:  J Heichel; H-G Struck
Journal:  Ophthalmologe       Date:  2017-05       Impact factor: 1.059

8.  Transcanalicular endoscopic primary dacryoplasty for congenital nasolacrimal duct obstruction.

Authors:  Nozomi Matsumura; Toru Suzuki; Satoshi Goto; Takeshi Fujita; Shin Yamane; Maiko Maruyama-Inoue; Kazuaki Kadonosono
Journal:  Eye (Lond)       Date:  2019-02-19       Impact factor: 3.775

9.  Effect of age on primary balloon dacryocystoplasty and probing success in congenital nasolacrimal duct obstruction.

Authors:  Volkan Dericioğlu; Mehmet Orkun Sevik; Sena Sümmen Saçu; Muhsin Eraslan; Eren Çerman
Journal:  Int Ophthalmol       Date:  2022-05-22       Impact factor: 2.029

10.  [Chronic dacryocystitis in a pediatric patient: transcanalicular endoscopic-assisted removal of iatrogenic foreign body from the lacrimal sac].

Authors:  J Heichel; H-G Struck; T Bredehorn-Mayr
Journal:  Ophthalmologe       Date:  2014-09       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.